Lars Björnebo, Shirin Razdan, Andrea Discacciati, Thorgerdur Palsdottir, Markus Aly, Tobias Nordström, Martin Eklund, Dara Lundon, Henrik Grönberg, Ash Tewari, Peter Wiklund, Natasha Kyprianou, Anna Lantz
BACKGROUND: α1-antagonists are commonly used to treat benign prostatic hyperplasia. Preclinical studies suggest they induce cell death and inhibit tumor growth. This study evaluates the risk of prostate cancer death in men using α1-antagonists. METHODS: A population-based cohort study in Stockholm, Sweden (January 1, 2007 to December 31, 2019) including 451,779 men with a prostate-specific antigen (PSA) test. Study entry was one year after the first PSA test...
May 8, 2024: Journal of the National Cancer Institute